+

WO2005092929A1 - Esters butyriques d'acide hyaluronique faiblement substitues, procede d'elaboration et utilisation - Google Patents

Esters butyriques d'acide hyaluronique faiblement substitues, procede d'elaboration et utilisation Download PDF

Info

Publication number
WO2005092929A1
WO2005092929A1 PCT/IB2005/000780 IB2005000780W WO2005092929A1 WO 2005092929 A1 WO2005092929 A1 WO 2005092929A1 IB 2005000780 W IB2005000780 W IB 2005000780W WO 2005092929 A1 WO2005092929 A1 WO 2005092929A1
Authority
WO
WIPO (PCT)
Prior art keywords
butyric
hyaluronic acid
esters
ester
salt
Prior art date
Application number
PCT/IB2005/000780
Other languages
English (en)
Italian (it)
Other versions
WO2005092929A8 (fr
Inventor
Danila Coradini
Alberto Perbellini
Original Assignee
Sintofarm S.P.A.
Ferlini, Giovanna
Perbellini, Giulia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sintofarm S.P.A., Ferlini, Giovanna, Perbellini, Giulia filed Critical Sintofarm S.P.A.
Priority to EP05718276A priority Critical patent/EP1781707A1/fr
Publication of WO2005092929A1 publication Critical patent/WO2005092929A1/fr
Publication of WO2005092929A8 publication Critical patent/WO2005092929A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Definitions

  • the sodium salt of butyric acid has the disadvantage of a very short half-life which strongly limits its clinical use due to the difficulties in achieving plasma concentrations which are sufficient to provide a therapeutic effect.
  • sodium butyrate when administered intravenously, sodium butyrate has a half-life of only 5 -6 minutes before being metabolised.
  • the chemical approach aimed at stabilizing the molecule by esterification in order to slow down its degradation and prolong its biological activity.
  • certain simple esters of butyric acid such as phenyl butyrate are known to exhibit antineoplastic activity in various forms of tumour such as prostate cancer (Proceedings of the American Association for Cancer Research, vol.
  • esterification simply has the purpose of increasing plasma half-life of the active principle, transforming the compound into a prodrug which on hydrolysis induces the slow release of butyric acid into the target organ.
  • the activity of these esters is always lower than that of the free acid due to the reduced bioavailability of the active principle.
  • esters of hyaluronic acid (HA) with butyric acid obtained by a procedure in which hyaluronic acid is dissolved in H 2 O, acidified and precipitated by adding collidine salts. Even though the HA is dissolved in dimethylformamide (DMF), the procedure is not completely anhydrous and the esters obtained have a degree of substitution (ratio of average mole value of butyric acid residues to number of moles of disaccharide units GlcNAc-GlcUA) never lower than 0.1.
  • DMF dimethylformamide
  • esters of the invention of cell proliferation was evaluated by MTT colorimetry and expressed as percentage inhibition compared to the control consisting of cells maintained in culture medium alone.
  • Panel B Shows the growth inhibition effect induced by three butyric esters (HB4,
  • HB10 and HB 11 compared with sodium butyrate in cell line HepB3.
  • liver sections of animals injected intrasplenically with tumour cells and treated with the esters of the invention Microscopic images depicting liver histology of animals injected intrasplenically with Lewis carcinoma LL3 cells and either treated or not treated with HA-But.
  • the 4 ⁇ m thick histological sections were taken from liver samples of treated or control animals, fixed in 10% formalin and enclosed in paraffin. After staining with Cajal- Gallego the sections were examined by optical microscope.
  • mice intrasplenically inoculated with B16/F10 melanoma cells and treated daily s.c. with HB10 at a dose of 4.8 ⁇ moles/mouse/day with weekly i.p boosters of 12 ⁇ moles/mouse on days 4, 11 , 18, 25, 31 was evaluated using the Kaplan-Meier method. After 90 days' observation, 8 out of 10 of the treated animals were still alive, as opposed to only 3 out of 11 of the control animals.
  • the present invention relates to hyaluronic acid butyric esters with a degree of substitution (ratio of average mole value of butyric residues to number of moles of disaccharide units GlcNAc-GlcUA of hyaluronic acid) being less than or equal to 0.1 and preferably less than or equal to 0.01.
  • esters characterised by a degree of substitution comprised from 0.001 to 0.08, preferably from 0.002 to 0.03 or even more preferably from 0.003 to 0.01.
  • the esters of the present invention have a hyaluronic acid molecular weight of between 10,000 and 100,000 D, even more preferably between 50,000 and 85,000 D.
  • esters of the present invention have demonstrated an antiproliferative, antitumour and antimetastatic activity, surprisingly greater than that of butyric esters characterised by a higher degree of substitution. Said effect is observed both in in vitro experiments on tumour cell lines and in in vivo experiments on animal models of metastatic dissemination.
  • esters of the invention are particularly active on primary and metastatic liver tumours and this activity seems to correlate with the levels of expression of CD44 on the tumor. Therefore, one of the main aspects of the invention relates to the use of the aforedefined esters for preparing drugs targeted for the treatment of pathologies characterised by cell hyperproliferation as in the case of tumours, particularly indicated for primary or metastatic liver tumours.
  • the esters of the invention compared to those of the prior art US 6,140,313 are obtained under anhydrous reaction conditions. Under these conditions the esterification reaction proceeds in a more controlled manner than under not fully anhydrous conditions, hence esters with low degrees of substitution can be obtained by suitably varying concentrations of the reagents.
  • the acylating agent is partially hydrolysed and, because of the poor solubility of hyaluronic acid in organic solvents, acylation takes place in a heterogeneous phase: the ester groups are thus distributed in a non-uniform manner on the polymer matrix.
  • the tetrabutylammonium salt (HA-TBA) is preferred, obtained according to known methods, for example by passing the sodium salt of hyaluronic acid over an ion exchanger conditioned with TBA.
  • a preferred ion exchanger is an amberlite resin IR 120 column in acid form, in which a 40% aqueous solution of TBA is recycled for at least 4 days at 40°C and subsequently washed with distilled H 2 O until the pH is ⁇ 10.
  • the hyaluronic acid quaternary salt is preferably dissolved in N,N- dimethylformamide (DMF) even if other solvents such as dimethyl sulfoxide (DMSO) or N-methylpyrrolidone can be used.
  • the process for preparing hyaluronic acid butyric esters with a degree of substitution less than or equal to 0.1 comprises the following passages: a) dissolving a hyaluronic acid quaternary nitrogen salt at a concentration between 1 and 100 g/litre in a polar aprotic solvent, optionally heating to temperatures above 50°C, b) preparing the acylating reagent by mixing, in a polar aprotic solvent, butyric anhydride and a 4-dialkylaminopyridine, c) adding the acylating reagent to the hyaluronic acid salt solution under anhydrous conditions, d) purifying the reaction product or alternatively converting the ester obtained into the corresponding sodium salt by means of acidification.
  • the acylating reaction is carried out under anhydrous conditions, for example under nitrogen atmosphere.
  • Preferred catalysts of the acylation reaction are 4- dialkylaminopyridines, among which 4-dimethylaminopyridine (DMAP) and 4- pyrrolidinopyridine (PPY).
  • DMAP 4-dimethylaminopyridine
  • PY 4- pyrrolidinopyridine
  • the hyaluronc acid is preferably prepared as HA-TBA in anhydrous DMF, at concentrations between 1 and 100 g/litre, more preferably between 10 and 50 g/litre, preferably heated to 80°C until dissolved then left to cool to ambient temperature.
  • a quantity of butyric anhydride at a concentration comprised from 0.01 to 5 moles/litre (preferably from 0.1 to 2 moles/litre) and of dimethylaminopyridine (DMAP) in a molar ratio with the butyric anhydride between 0.1 and 10 (preferably between 0.5 and 2 or actually in an equimolar ratio with the butyric anhydride quantity), in a suitable volume of anhydrous DMF, are added drop-wise to the HA- TBA solution, under mechanical agitation, leaving it to react for at least an hour. The reaction is then stopped with distilled H 2 O.
  • DMAP dimethylaminopyridine
  • the acylating reagent is added in a quantity such that the molar ratio between butyric anhydride and the repeating disaccharide unit of hyaluronic acid is between 0.004 and 0.3, preferably between 0.008 and 0.1 , or even more preferably between 0.01 and 0.03.
  • a further aspect of the invention relates to the possibility of obtaining pharmaceutical compositions containing, as active principle, a therapeutically efficient quantity of a butyric ester of the invention in association with suitable pharmaceutically acceptable diluents and excipients.
  • said compositions can also contain other active principles and can be employed for oral use, in the form of granular powders, tablets, pills or gels.
  • the administration of the butyric esters of the invention can be systemic, oral, parenteral, topical or transdermal, they also being suitable for administration via the following routes: oral, intravenous, intraperitoneal, intraarticular, intramuscular, subcutaneous, rectal, intracavital (intravesicular or intravaginal).
  • the effective therapeutic dose varies preferably from 0.2 to 2 g/day for 1-15 days or, more preferably, from 0.3 and 1.5 g/day.
  • the butyric esters of the invention are non- toxic and can therefore be used at the proposed doses or at even higher doses.
  • the butyric ester is administered preferably at the dose of 0.2-50 mg/kg/day for 8-12 days. If injected intraperitoneally, the butyric ester is preferably administered as a solution, preferably in physiological solution, at a dose of 1-100 mg/kg/day (preferably 10-50 mg/kg/day) for 8-12 days.
  • the butyric ester is preferably administered at a dose of 300-500 mg/kg/day for 8-12 days.
  • the new esters of the invention in which butyric acid is esterified with HA are characterised by a high affinity for a specific membrane receptor (CD44). This specificity is therefore exploitable for preferentially delivering the drug to target cells which express high levels of said receptor. Due to their specificity, the esters of the invention are an effective solution to the treatment of neoplastic lesions surrounded by normal tissue, such as intrahepatic lesions, with greatly reduced cell damage to normal cells as normally occurs with classical treatments with cytotoxic drugs.
  • Da Dalton (unit of atomic mass) [equivalent to g/mole]
  • HA-Na sodium salt of hyaluronic acid sodium hyaluronate
  • the ion exchange resin Amberlite IR-120 (plus) in the form of tetrabutylammonium salt (TBA) was obtained from that in acid form (Sigma-Aldrich) by treatment with an aqueous 40 weight.% solution of tetrabutylammonium hydroxide, recycled for 4 days through a jacketed column at 40°C.
  • HA-Na 500 g - 1.25 eq ⁇ moles of repeating dimer units
  • the solution was loaded and recycled in cocurrent (descending flow with velocity of ⁇ 100 ml/minute) for ⁇ 24 hours through a column containing Amberlite IR-120 (plus) ion exchange resin in the form of TBA salt (7 kg - 30.8 eq).
  • the column was unloaded and the resin washed with bidistilled water ( ⁇ 13 litres) to recover all the residual product.
  • the conversion from the tetrabutylammonium salt (TBA) to the sodium salt (Na) of the HA-But product was undertaken by acidification with 0.1 M hydrochloric acid (HCI) and neutralization with a saturated sodium hydrogen carbonate (NaHCO 3 ) solution.
  • HCI hydrochloric acid
  • NaHCO 3 saturated sodium hydrogen carbonate
  • the solution was then concentrated to about one fifth of the original volume with a rotary evaporator under reduced pressure; the polymer was then precipitated by pouring the concentrated solution into at least three volumes of acetone, then the precipitate was separated by filtration and dried under vacuum.
  • the product obtained was then purified by dialysis of the aqueous solution of the crude solid against distilled water, using cellulose membrane dialysis tubes with a molecular weight cut-off equal to 12-14 kDa (Visking).
  • the butyric esters of hyaluronic acid in the form of sodium salt were then obtained, by lyophilising, as white or whitish solids.
  • the structure of the compounds was determined by proton magnetic resonance spectroscopy ( 1 H-NMR), undertaken on deuterated dimethylsulfoxide solutions (DMSO-d6) at 200 or 500 MHz using Bruker 200 AC or Varian Inova 500 spectrometers, respectively.
  • the compound with the lowest degree of substitution (0.004 - HB10) was found to induce, in the HT29 cells, a 50% inhibition at a concentration (in terms of butyrate) about 60 times lower than that required to obtain the same effect with the active principle (figure 3A). All the butyric monoesters tested also showed a dose-dependent inhibitory effect on Hep3B cells which was clearly greater than that exerted by the active principle alone (figure 3B). In these cells in particular, the compound with the lowest degree of substitution was found to be capable of inhibiting cell growth by 50° ⁇ at a concentration (in terms of butyrate) about 120 times lower than that necessary to obtain the same effect with the active principle.
  • the cells were incubated with propidium iodide (5 g/ml), RNase (10 kU/ml), (Sigma), and Nonidet P40 (0.005%) and fluorescence was measured with a FAC Scan flow cytometer (Becton Dickinson, San Jose, CA) equipped with argon laser. The fluoresce nt signal was acquired in both linear mode and logarithmic mode. The cytometr ⁇ c examination demonstrated that only 18% of the HepG2 cells express CD44 receptors on their cell surfaces, in contrast to 78% of HepB3 cells (figure 5A).
  • HA-But was found to be much more effective than sodium butyrate with an approximately 10 fo ld reduction in IC 50 value compared to that observable with the active principle alone (2.1 vs 0.12 mM in HepG2 cells and 3 vs 0.31 mM in HepB3 cells) suggesting that the use of a suitable carrier can significantly increase biological activity of the sodium butyrate without negatively influencing its biological activity due to the presence of a bulky molecule such as that of HA.
  • Example 6 Evaluation of binding kinetics with labelled butyric esters. In vitro and in vivo studies.
  • mice strains C57BL/6, C57BL/6xDBA/2F1 (BD2F1) and CBA/Lac were used acquired from Harlan & Nossan, San Rafael al Natisone, Udine, Italy, aged from 3 to 6 months and weighing 18-20 g. All the experiments were conducted in accordance with the regulations currently in force in Italy (DDL 116, 21/12/92) and The Guide for the Care and Use of Laboratory Animals. (DHHS Publ. No [NIH], 86-23, Bethesda, MD: NIH, 1985). Cells.
  • tumour cells thus obtained were then inoculated intrasplenically in a sterile environment, into female strain BD2F1 mice previously anaesthetised by i.p injection with Zoletil (70 mg/kg) (Virbac srl, Milan, Italy).
  • Zoletil 70 mg/kg
  • About 2x10 5 Lewis LL3 carcinoma cells or 1x10 5 B16/F10 melanoma cells were inoculated after suitably dissolving in a Matrigel solution (150 ⁇ g/ml, Beckton Dickinson) to enable a better implantation in the organ. 4 days after the inoculation, (required to allow the tumour cells to implant), groups of 8 animals were each treated i.p. or s.c.
  • HA-But whose carrier molecule (HA) is characterised by a high affinity for a specific membrane receptor known to be overexpressed by the tumour cells, could constitute a turning point in the treatment of primary and metastatic intrahepatic lesions of other origins.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des esters butyriques d'acide hyaluronique dans lesquels les groupes hydroxyle de l'acide hyaluronique sont partiellement estérifiés par des groupes fonctionnels butyriques, caractérisés par un taux de substitution par les groupes fonctionnels butyriques inférieur à 0,1 (nombre de groupes fonctionnels butyriques rapporté au nombre d'unités disaccharide GIcNAc-GIcUA de l'acide hyaluronique). Ces esters faiblement substitués résultent d'un traitement mené en phase homogène dans des conditions anhydres, l'acide hyaluronique étant utilisé sous forme d'un sel d'azote quaternaire. Les esters de l'invention présentent un pouvoir antiproliférant supérieur à celui des esters correspondants plus fortement substitués. Ils sont particulièrement actifs contre les tumeurs primaires et métastatiques, notamment dans le cas de tumeurs primaires d'origine hépatique, ou de métastases hépatiques. Un autre aspect de l'invention concerne des compositions pharmaceutiques dont le principe actif est l'un au moins des esters de l'invention.
PCT/IB2005/000780 2004-03-29 2005-03-25 Esters butyriques d'acide hyaluronique faiblement substitues, procede d'elaboration et utilisation WO2005092929A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05718276A EP1781707A1 (fr) 2004-03-29 2005-03-25 Esters butyriques d'acide hyaluronique faiblement substitues, procede d'elaboration et utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2004A000605 2004-03-29
ITMI20040605 ITMI20040605A1 (it) 2004-03-29 2004-03-29 Esteri butirrici dell'acido ialuronico a basso grado di sostituzione procedimento per la loro preparazione ed uso

Publications (2)

Publication Number Publication Date
WO2005092929A1 true WO2005092929A1 (fr) 2005-10-06
WO2005092929A8 WO2005092929A8 (fr) 2006-03-02

Family

ID=34967092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000780 WO2005092929A1 (fr) 2004-03-29 2005-03-25 Esters butyriques d'acide hyaluronique faiblement substitues, procede d'elaboration et utilisation

Country Status (3)

Country Link
EP (1) EP1781707A1 (fr)
IT (1) ITMI20040605A1 (fr)
WO (1) WO2005092929A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100305061A1 (en) * 2007-11-27 2010-12-02 Sigea S.R.L. Mixed butyric-formic esters of acid polysaccharides, and their preparation and use as skin cosmetics
EP2319503A2 (fr) * 2008-05-29 2011-05-11 Soon-Chang Kwon Vecteur d'administration de médicament
US8247546B2 (en) * 2006-12-29 2012-08-21 Siega S.R.L. Derivatives of acid polysaccharides
EP2522337A2 (fr) 2011-05-13 2012-11-14 Rottapharm S.P.A. Esters d'acide hyaluronique, leur préparation et leur utilisation en dermatologie
CN103724455A (zh) * 2013-12-11 2014-04-16 四川大学 一种透明质酸衍生物及其水凝胶的制备方法
WO2014082609A1 (fr) 2012-11-27 2014-06-05 Contipro Biotech S.R.O. Dérivé de l'acide hyaluronique acylé par un groupe acyle en c6-c18, son procédé de préparation, composition nanomicellaire à base de celui-ci, son procédé de préparation et procédé de préparation de composition nanomicellaire stabilisée et son utilisation
WO2015074632A1 (fr) 2013-11-21 2015-05-28 Contipro Biotech S R.O. Nanofibres contenant un dérivé ester photodurcissable de l'acide hyaluronique ou de son sel, nanofibres photodurcies, leur procédé de synthèse, préparation contenant des nanofibres photodurcies et son utilisation
WO2016113192A1 (fr) * 2015-01-13 2016-07-21 Sigea S.R.L. Procédé de préparation d'esters butyriques de sel de sodium d'acide hyaluronique en milieu aqueux
US10023658B2 (en) 2014-03-11 2018-07-17 Contipro A.S. Conjugates of oligomer of hyaluronic acid or of a salt thereof, method of preparation thereof and use thereof
US10414832B2 (en) 2015-06-26 2019-09-17 Contipro A.S Derivatives of sulfated polysaccharides, method of preparation, modification and use thereof
US10618984B2 (en) 2016-06-27 2020-04-14 Contipro A.S. Unsaturated derivatives of polysaccharides, method of preparation thereof and use thereof
US10617711B2 (en) 2014-06-30 2020-04-14 Contipro A.S. Antitumor composition based on hyaluronic acid and inorganic nanoparticles, method of preparation thereof and use thereof
US10689464B2 (en) 2015-03-09 2020-06-23 Contipro A.S. Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of preparation and use thereof
US10759878B2 (en) 2015-06-15 2020-09-01 Contipro A.S. Method of crosslinking of polysaccharides using photoremovable protecting groups

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116444695B (zh) * 2022-12-27 2024-09-06 山东丰金美业科技有限公司 一种低成本、低分子量乙酰化透明质酸钠的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023648A1 (fr) * 1996-11-29 1998-06-04 Societa' Cooperativa Centro Ricerche Poly-Tech A Responsabilita' Limitata Esters butyriques a action antiproliferative et compositions pharmaceutiques les contenant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023648A1 (fr) * 1996-11-29 1998-06-04 Societa' Cooperativa Centro Ricerche Poly-Tech A Responsabilita' Limitata Esters butyriques a action antiproliferative et compositions pharmaceutiques les contenant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CORADINI D ET AL: "Hyaluronic acid as drug delivery for sodium butyrate: improvement of the anti-proliferative activity on a breast-cancer cell line", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 81, no. 3, 5 May 1999 (1999-05-05), pages 411 - 416, XP002245583, ISSN: 0020-7136 *
KAWAGUCHI Y ET AL: "The relation between the adsorption behavior at the interface and the conformational changes in hyaluronates partially modified with various acyl chains", CARBOHYDRATE POLYMERS, APPLIED SCIENCE PUBLISHERS, LTD. BARKING, GB, vol. 26, no. 2, 1995, pages 149 - 154, XP004034490, ISSN: 0144-8617 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8247546B2 (en) * 2006-12-29 2012-08-21 Siega S.R.L. Derivatives of acid polysaccharides
AU2007341078B2 (en) * 2006-12-29 2013-03-07 Sigea S.R.L. Derivatives of acid polysaccharides
US8530450B2 (en) * 2007-11-27 2013-09-10 Sigea S.R.L. Mixed butyric-formic esters of acid polysaccharides, and their preparation and use as skin cosmetics
US20100305061A1 (en) * 2007-11-27 2010-12-02 Sigea S.R.L. Mixed butyric-formic esters of acid polysaccharides, and their preparation and use as skin cosmetics
EP2319503A2 (fr) * 2008-05-29 2011-05-11 Soon-Chang Kwon Vecteur d'administration de médicament
EP2319503A4 (fr) * 2008-05-29 2012-12-05 Kwon Soon Chang Vecteur d'administration de médicament
EP2522337A2 (fr) 2011-05-13 2012-11-14 Rottapharm S.P.A. Esters d'acide hyaluronique, leur préparation et leur utilisation en dermatologie
US9062129B2 (en) 2011-05-13 2015-06-23 Rottapharm S.P.A. Hyaluronic acid esters, their preparation and use in dermatology
WO2014082609A1 (fr) 2012-11-27 2014-06-05 Contipro Biotech S.R.O. Dérivé de l'acide hyaluronique acylé par un groupe acyle en c6-c18, son procédé de préparation, composition nanomicellaire à base de celui-ci, son procédé de préparation et procédé de préparation de composition nanomicellaire stabilisée et son utilisation
US9999678B2 (en) 2012-11-27 2018-06-19 Contipro A.S. C6-C18-acylated derivative of hyaluronic acid and method of preparation thereof
WO2015074632A1 (fr) 2013-11-21 2015-05-28 Contipro Biotech S R.O. Nanofibres contenant un dérivé ester photodurcissable de l'acide hyaluronique ou de son sel, nanofibres photodurcies, leur procédé de synthèse, préparation contenant des nanofibres photodurcies et son utilisation
CN103724455A (zh) * 2013-12-11 2014-04-16 四川大学 一种透明质酸衍生物及其水凝胶的制备方法
CN103724455B (zh) * 2013-12-11 2016-07-06 四川大学 一种透明质酸衍生物及其水凝胶的制备方法
US10023658B2 (en) 2014-03-11 2018-07-17 Contipro A.S. Conjugates of oligomer of hyaluronic acid or of a salt thereof, method of preparation thereof and use thereof
US10617711B2 (en) 2014-06-30 2020-04-14 Contipro A.S. Antitumor composition based on hyaluronic acid and inorganic nanoparticles, method of preparation thereof and use thereof
WO2016113192A1 (fr) * 2015-01-13 2016-07-21 Sigea S.R.L. Procédé de préparation d'esters butyriques de sel de sodium d'acide hyaluronique en milieu aqueux
JP2018501385A (ja) * 2015-01-13 2018-01-18 シジェア ソシエタ ア レスポンサビリタ リミタータ ヒアルロン酸ナトリウム塩の酪酸エステルの調製のための水中における方法
RU2708994C2 (ru) * 2015-01-13 2019-12-12 Сиджеа С.Р.Л. Проводимый в воде способ получения сложных эфиров масляной кислоты и натриевой соли гиалуроновой кислоты
US10618982B2 (en) 2015-01-13 2020-04-14 Bmg Pharma S.P.A. Process in water for the preparation of butyric esters of hyaluronic acid sodium salt
KR20170105010A (ko) * 2015-01-13 2017-09-18 시제아 에스.알.엘 히알루론산 나트륨 염의 부티르산 에스테르의 수중 제조 방법
KR102636528B1 (ko) 2015-01-13 2024-02-15 시제아 에스.알.엘 히알루론산 나트륨 염의 부티르산 에스테르의 수중 제조 방법
US10689464B2 (en) 2015-03-09 2020-06-23 Contipro A.S. Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of preparation and use thereof
US10759878B2 (en) 2015-06-15 2020-09-01 Contipro A.S. Method of crosslinking of polysaccharides using photoremovable protecting groups
US10414832B2 (en) 2015-06-26 2019-09-17 Contipro A.S Derivatives of sulfated polysaccharides, method of preparation, modification and use thereof
US10618984B2 (en) 2016-06-27 2020-04-14 Contipro A.S. Unsaturated derivatives of polysaccharides, method of preparation thereof and use thereof

Also Published As

Publication number Publication date
ITMI20040605A1 (it) 2004-06-29
WO2005092929A8 (fr) 2006-03-02
EP1781707A1 (fr) 2007-05-09

Similar Documents

Publication Publication Date Title
WO2005092929A1 (fr) Esters butyriques d'acide hyaluronique faiblement substitues, procede d'elaboration et utilisation
Yang et al. Scutellarin-cyclodextrin conjugates: synthesis, characterization and anticancer activity
Luo et al. Synthesis and selective cytotoxicity of a hyaluronic acid− antitumor bioconjugate
Li et al. Coassembled nanostructured bioscaffold reduces the expression of proinflammatory cytokines to induce apoptosis in epithelial cancer cells
US7005426B2 (en) Folic acid-polysaccharide complex, its preparation method and pharmaceutical composition containing the same as active component
BR112012029975B1 (pt) peptídeo e composição farmacêutica como medicamento
AU6488099A (en) Dds compounds and method for assaying the same
Wu et al. Structural analysis and anti-cancer activity of low-molecular-weight chondroitin sulfate from hybrid sturgeon cartilage
CN109678987B (zh) 一种硫化氢释放剂ha-adt、其制备方法及应用
KR101790649B1 (ko) 글리코사미노글리칸 화합물 및 이의 제조 방법과 용도
KR20210040359A (ko) 섬유성 유착 치료를 위한 고황산화 푸칸
Wu et al. Enhanced solubility of curcumin by complexation with fermented cyclic β-1, 2-glucans
Zhou et al. Pectin-based self-healing hydrogel through acylhydrazone connection for controlled drug release and enhanced tumor therapy
BR112013027389B1 (pt) Processo para o preparo de sal sódico de sulfato de condroitina
WO2017206477A1 (fr) Composé pharmaceutique de liaison ca4 polymère et son procédé de préparation
TWI771652B (zh) Cd44靶向多臂偶聯物
CN111789964B (zh) 具有还原响应性的硒类聚合物前药胶束、制备方法和应用
Ruhela et al. Chemoenzymatic synthesis of oligohyaluronan–lipid conjugates
CN105412011A (zh) 一种载体本身具有抗肿瘤和抗转移活性的两亲性胶束
CN102952207B (zh) 6-(1-甲基-β-咔啉-3-羧酸乙酰基)-6-脱氧-β-环糊精及其与阿霉素超分子包结配合物的制备和应用
Long et al. Preparation and evaluation of water-soluble chondroitin sulfate-curcumin conjugate
Tang et al. Synthesis, characterization, and in vitro and in vivo evaluation of a novel pectin–adriamycin conjugate
CN102746346A (zh) 以碳原子为连接点的富勒烯单糖衍生物及其制备方法
IT201800009731A1 (it) Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante
Li et al. Hyaluronic acid based hypoxia-responsive aggregation-induced emission fluorescent probe for tumor cell imaging

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 40/2005 UNDER (71) ADD "PERBELLINI, GIULIA (HEIRESS OF THE DECEASED INVENTOR) [IT/IT]; VIA IV NOVEMBRE, 14, I-37126 VERONA (IT)."

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005718276

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005718276

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005718276

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载